| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Telmisartan, ramipril, or both in patients at high risk for vascular events.
|
N Engl J Med
|
2008
|
19.76
|
|
2
|
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
|
Lancet
|
2008
|
13.34
|
|
3
|
Telmisartan to prevent recurrent stroke and cardiovascular events.
|
N Engl J Med
|
2008
|
7.25
|
|
4
|
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
|
Lancet
|
2008
|
7.05
|
|
5
|
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.
|
Circulation
|
2007
|
2.76
|
|
6
|
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
|
Circulation
|
2010
|
2.74
|
|
7
|
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
|
J Hypertens
|
2009
|
2.68
|
|
8
|
Changes in albuminuria predict mortality and morbidity in patients with vascular disease.
|
J Am Soc Nephrol
|
2011
|
2.40
|
|
9
|
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
|
Circulation
|
2012
|
2.25
|
|
10
|
Effect of telmisartan on renal outcomes: a randomized trial.
|
Ann Intern Med
|
2009
|
1.85
|
|
11
|
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.
|
JAMA Intern Med
|
2013
|
1.78
|
|
12
|
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
|
Circulation
|
2011
|
1.77
|
|
13
|
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
|
Circulation
|
2011
|
1.65
|
|
14
|
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.
|
Hypertension
|
2015
|
1.57
|
|
15
|
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
|
J Hypertens
|
2012
|
1.49
|
|
16
|
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.
|
Hypertension
|
2014
|
1.49
|
|
17
|
Healthy eating and reduced risk of cognitive decline: A cohort from 40 countries.
|
Neurology
|
2015
|
1.46
|
|
18
|
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
|
J Am Coll Cardiol
|
2012
|
1.28
|
|
19
|
Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.
|
Circulation
|
2012
|
1.24
|
|
20
|
Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND.
|
Clin Res Cardiol
|
2013
|
1.16
|
|
21
|
Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies.
|
Arch Intern Med
|
2011
|
1.14
|
|
22
|
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
|
Lancet Neurol
|
2010
|
1.10
|
|
23
|
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.
|
Diabetes Metab Syndr Obes
|
2014
|
1.05
|
|
24
|
Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.
|
Clin J Am Soc Nephrol
|
2012
|
0.93
|
|
25
|
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
|
Circulation
|
2009
|
0.93
|
|
26
|
Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study.
|
Diabetes Care
|
2011
|
0.87
|
|
27
|
In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.
|
PLoS One
|
2010
|
0.85
|
|
28
|
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.
|
Am Heart J
|
2013
|
0.84
|
|
29
|
Risk Prediction for Early CKD in Type 2 Diabetes.
|
Clin J Am Soc Nephrol
|
2015
|
0.82
|
|
30
|
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
|
Eur J Prev Cardiol
|
2013
|
0.81
|
|
31
|
Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union.
|
Nephrol Dial Transplant
|
2015
|
0.79
|
|
32
|
A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND.
|
PLoS One
|
2014
|
0.75
|
|
33
|
Dual RAS blockade-controversy resolved.
|
Nat Rev Nephrol
|
2013
|
0.75
|
|
34
|
[Critically appraised article].
|
Rev Med Chil
|
2012
|
0.75
|